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As per our protocol, these patients were followed with routine laboratory investigations at weekly intervals for the first 3 months, fortnightly for the next 3 months, monthly for the next 6 months, and three monthly intervals thereafter. During each visit, kidney and liver function statuses were monitored; complete blood counts, ultrasound, and Doppler studies were performed. Kidney biopsy was done when there was a persistent rise in serum creatinine and proteinuria either new onset or ≥3 g/day. During infections, apart from blood cultures and urine cultures, appropriate investigations for diagnosing suspected infective agents were done.
All patients were followed up to the point of graft loss or death.
Statistical analysis
Statistical analysis was performed using R Software, foundation (Ross Ihaka and Robert Gentleman at the University of Auckland, New Zealand). Demographic characteristics were summarized with descriptive statistics (mean and standard deviation for continuous variables and frequency and percentages for categorical variables). The Friedman test, a nonparametric alternative to the one-way ANOVA with repeated measures, was performed to compare the serum creatinine on various time points. P < 0.05 was considered statistically significant.
rEsults

Patient demographics
A total of 105 kidney transplant recipients including 81 men (77.14%) and 24 women (22.85%) were included in the analysis. The cause of deaths were road traffic accidents77grafts(73.35%), fall from height -18 grafts(17.14%), fall at home -2 grafts(1.9%), aneurysmal bleed -5 grafts (4.75%) and traumatic asphyxia -1 graft (0.9%). Three were expanded criteria deceased donors. Most of the grafts (56%) were from the right side. The mean duration of dialysis in our recipient group was 20.1 months with minimum of 1 month and maximum of 60 months on dialysis. Our center was the source of kidney in 41 deceased donor transplantations (39.04%).
Baseline demographics and clinical characteristics of the patients have been given in Table 1 (n = 91).
Cold ischemic times
In our series, the mean cold ischemic time (CIT) was 8.01 (±2.73) h in deceased donor kidney transplantation. When graft was harvested from our center, the CIT was 3 h, and when the graft was harvested from other centers, CIT was 15 h. It was noted that there was no difference in graft function among groups with CIT <8 h and with CIT beyond 12 h.
Our transplantation protocol
We started using basiliximab from October 2010 and antithymocyte globulin rabbit origin (rATG) from October 2012 as induction agents. A single dose of 1.5 mg/kg of rATG was given as intravenous infusion in the preoperative and intraoperative period. Valganciclovir 450 mg twice daily is given for 3 months for cytomegalovirus prophylaxis if ATG is used. We also used interleukin -2 receptor blockers (basiliximab), given as two doses of 20 mg each. The first dose was given just before surgery followed by the second dose 4 days later.
The immunosuppression regimen mainly included cyclosporine/tacrolimus, mycophenolate mofetil/azathioprine, and prednisolone [ Table 2 ].
Assessment of kidney function
The mean serum creatinine levels were 2.43 ± 2.07 mg/dL at the 1 st week after transplant, 1.49 ± 1.05 mg/dL at the 1 st month, and 1.24 ± 0.48 mg/dL at the 6 th month after transplant [ Figure 1 ]. Change in serum creatinine levels was statistically significant (P < 0.05).
Graft function, rejection, and loss
Normal graft function was observed in 59 (56.19%) recipients followed by graft dysfunction in 17 recipients, out of which 9 became dialysis dependent. Delayed graft function (DGF) (requirement of hemodialysis within the 1 st week of transplant) occurred in 16 (15.24%) recipients. Graft rejection was observed in 18 recipients (17.14%). Details of graft rejection have been shown in Table 3 . 
Posttransplant complications
One of the most common posttransplant medical complications was acute tubular necrosis (12.4%), followed by pneumonitis (5.71%), new-onset diabetes after transplant (5.71%), posttransplant erythrocytosis (4.8%), and sepsis (5.71%). The significant posttransplant complications and surgical complications have been summarized in Table 4 .
Kidney biopsy was done for 35 recipients (33.33%). The findings revealed early acute cellular rejection (ACR) -8 (22%), late ACR -4 (3.81%), ACR/acute humoral rejection -2 (5.7%), antibody-mediated rejection (ABMR) − 2 (5.7%), ACR/chronic active ABMR -2 (5.7%), acute tubular necrosis -14 (40%), chronic allograft nephropathy/interstitial fibrosis and tubular atrophy -5 (14.28%), calcineurin inhibitor toxicity -2 (5.7%), hemolytic-uremic syndrome -1 (2.8%), and cortical necrosis -1 (2.85%).
Patient survival
Twenty-nine (27.6%) transplant recipients expired during follow-up. The median survival time after transplant was 23 months (n = 105). Since ours is a tertiary care center, patients were referred to us after long period of hemodialysis. The patients had lower standard of living accounting for increased incidence of sepsis which might have contributed to the low survival.
ConClusions
The survival rates of our 96 recipients who have completed minimum of 1 year of follow-up, shown in Table 5 are as follows. The 1-year recipients' survival rate was 75% and 1-year graft survival rate was 89.58%.
Although the graft rejection rates (18%) were quite low in our center, the mortality rate was quite high (27.6%). The overall outcomes of deceased donor transplantation in our series are compared with other series, as shown in Tables 6 and 7 .
The occurrence of death in various time periods after transplant was <1 month: 5 patients (17.24%), 1 month-3 months: 7 patients (24.13%), 3 months-6 months: 6 patients (20.68%), 6 months-1 year: 6 patients (20.68%), and >1 year: 5 patients (17.24%). The majority of the deaths occurred within the early transplant period. The cause of death of 29 recipients was sepsis in 22 recipients (75.86%), cardiovascular events in 5 recipients (17.24%), and graft artery thrombosis in 2 recipients (6.8%). Sepsis contributed to the majority of mortality. Since our patients were from lower socioeconomic status, they probably might not tolerated immunosuppresion. The use of induction agents could also have contributed to the increased incidence of sepsis leading to death. [3]
In a study involving 309 patients from a deceased donor kidney transplantation center of Mannheim, transplantation was associated with a lower HR (0.36, 95% confidence interval: 0.15-0.87) compared to the wait-listed group (1.00). The mortality rate was 0.026 per patient-year (0.032 on dialysis compared to 0.016 with functioning graft). [4] Few transplant centers in India have made significant contributions in the field of deceased donor kidney transplantation. [1] In a retrospective analysis of 68 deceased donor kidney transplantation by Prabahar and Soundararajan, the 5-year patient and graft survival rates were 61.7% and 58.8%, respectively. [5] In another retrospective study of 38 deceased donor kidney transplantation by Feroz et al., the graft survival rate was 85% and was associated with satisfactory patient and graft survival, despite the high incidence of DGF (68%). [2] Our series had comparable graft function with other series in India. Moyers et al. had reported a better graft outcome in spite of having higher CITs. [10] This probably could be due to postoperative factors such as higher dose of immunosuppression given in western countries which our nephrologists here find it difficult to administer due to fear for infections. Most of these deaths in our series were caused by sepsis. It is possible that long duration of hemodialysis before transplant, extended criteria donor, increased DGF, triple immunosuppressive regimens with ATG induction, a delayed presentation leading to late diagnosis, tropical climate, and socioeconomic factors may have contributed to high infection rate leading to a higher 1-year posttransplantation mortality, with most of these deaths caused by sepsis. [12] [13] [14] As brought out by Samhan et al., the recipients of kidney allograft in developing countries may be more prone to infections, which are the most common cause of posttransplant mortality. [15] It is necessary to take steps to minimize ischemia times and use of better perfusion techniques and optimize the dose of immunosuppressants as low as possible for better outcomes in deceased donor transplantation. Despite tremendous potential, a deceased donor kidney transplantation program has not been developed in many centers. We should also create more awareness and involve various community programs to increase the incidence of deceased donor transplantation.
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